Novo Nordisk is trading 5.76% down now at $40.61 as its September 21, 2026 Capital Markets Day raises investor concerns about the company’s growth outlook.
- Management plans to launch more than five blockbuster drugs by 2030 and generate over 150 billion Danish kroner in pipeline sales by 2035.
- Analysts questioned pricing power and dealmaking strategy amid looming patent expiries.
- The decline is company-specific: major U.S. indices are rising, while shares fell as much as 7% during the strategy update.